CO4410321A1 - Compuestos ciclicos condensados con funciones aminoacidas sustituidas y derivados ester de los mismos - Google Patents

Compuestos ciclicos condensados con funciones aminoacidas sustituidas y derivados ester de los mismos

Info

Publication number
CO4410321A1
CO4410321A1 CO95036221A CO95036221A CO4410321A1 CO 4410321 A1 CO4410321 A1 CO 4410321A1 CO 95036221 A CO95036221 A CO 95036221A CO 95036221 A CO95036221 A CO 95036221A CO 4410321 A1 CO4410321 A1 CO 4410321A1
Authority
CO
Colombia
Prior art keywords
amino acid
substituted amino
ester derivatives
acid functions
condensed compounds
Prior art date
Application number
CO95036221A
Other languages
English (en)
Inventor
Helton David Reed
James Allen Monn
Roger Lewis Robey
Darwin Schoepp Darryle
Joseph Patrick Tizzano
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO4410321A1 publication Critical patent/CO4410321A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/30—Unsaturated compounds
    • C07C62/38—Unsaturated compounds containing keto groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

REIVINDICACION NUMERO UN COMPUESTO DE LA FORMULA FIGURA 1 EN DONDE: X ES (CH2)n: R2 ES CO2R4 Y R3 ES HIDROGENO, O R2 ES HIDROGENO Y R3 ES CO2R4; R1 Y R4 SON INDEPENDIENTEMENTE HIDROGENO, C1-C10 ALQUILO, C2-C10ALQUENILO, ARILO O ARILALQUILO; Y n ES 1; O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO". REIVINDICACION NUMERO 1UN COMPUESTO DE LA FORMULA FIGURA 2 DONDE: X ES (CH2)n; n ES 1; R2a ES CO2R4a Y R3a ES HIDROGENO, O R2a ES HIDROGENO Y R3a ES CO2R4a; y R4a ES UN GRUPO PROTECTOR CARBOXI".
CO95036221A 1994-08-12 1995-08-14 Compuestos ciclicos condensados con funciones aminoacidas sustituidas y derivados ester de los mismos CO4410321A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28995794A 1994-08-12 1994-08-12
US33734994A 1994-11-10 1994-11-10
US08/496,643 US5750566A (en) 1994-08-12 1995-06-29 Synthetic excitatory amino acids

Publications (1)

Publication Number Publication Date
CO4410321A1 true CO4410321A1 (es) 1997-01-09

Family

ID=26965934

Family Applications (1)

Application Number Title Priority Date Filing Date
CO95036221A CO4410321A1 (es) 1994-08-12 1995-08-14 Compuestos ciclicos condensados con funciones aminoacidas sustituidas y derivados ester de los mismos

Country Status (5)

Country Link
US (2) US5750566A (es)
KR (1) KR100375463B1 (es)
BR (1) BR9503638A (es)
CO (1) CO4410321A1 (es)
UA (1) UA43332C2 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL182285B1 (pl) * 1994-08-12 2001-12-31 Lilly Co Eli Syntetyczne aminokwasy oraz ich estry i srodki farmaceutyczne je zawierajace PL PL PL PL PL PL PL
WO1996004901A1 (en) * 1994-08-12 1996-02-22 Eli Lilly And Company Composition and method for treating anxiety
ZA969485B (en) * 1995-11-16 1998-05-12 Lilly Co Eli Excitatory amino acid receptor antagonists.
US5824662A (en) * 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
US6017903A (en) 1996-09-27 2000-01-25 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
NZ334780A (en) 1996-09-27 2000-12-22 Guilford Pharm Inc Use of a NAALADase inhibitor for treating glutamate abnormality and effecting neuronal activity in animals
ZA983930B (en) * 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
US6528271B1 (en) * 1997-06-05 2003-03-04 Duke University Inhibition of βarrestin mediated effects prolongs and potentiates opioid receptor-mediated analgesia
US7541151B2 (en) 1997-06-05 2009-06-02 Duke University Single-cell biosensor for the measurement of GPCR ligands in a test sample
US5891646A (en) * 1997-06-05 1999-04-06 Duke University Methods of assaying receptor activity and constructs useful in such methods
US6124361A (en) * 1997-12-31 2000-09-26 Pfizer Inc Bicyclo[3.1.0]hexanes and related compounds
ATE236118T1 (de) 1998-01-28 2003-04-15 Taisho Pharmaceutical Co Ltd Fluorhaltige aminosäurederivate
US6521561B1 (en) 1998-05-01 2003-02-18 President And Fellows Of Harvard College Main-group metal based asymmetric catalysts and applications thereof
EP1110943B1 (en) 1998-08-31 2004-06-16 Taisho Pharmaceutical Co. Ltd. 6-fluorobicyclo 3. 1.0]hexane derivatives
PE20001236A1 (es) * 1998-11-13 2000-11-10 Lilly Co Eli Moduladores del receptor de aminoacidos excitadores
US6479674B1 (en) * 1999-03-25 2002-11-12 Taisho Pharmaceutical Co., Ltd. Carboxylic acid derivatives and process for producing same
JP4505926B2 (ja) * 1999-03-25 2010-07-21 大正製薬株式会社 新規カルボン酸誘導体及びその製造方法
JP4192331B2 (ja) * 1999-04-16 2008-12-10 住友化学株式会社 光学活性２−オキソビシクロ［３．１．０］ヘキサン−６−カルボン酸誘導体の製造方法
WO2002055485A1 (en) * 2001-01-11 2002-07-18 Eli Lilly And Company Prodrugs of excitatory amino acids
HUP0400620A3 (en) * 2001-01-11 2012-09-28 Lilly Co Eli Prodrugs of excitatory amino acids and pharmaceutical compositions containing them and process for preparation the compounds
EP1310482A1 (en) * 2001-11-07 2003-05-14 Eli Lilly And Company Prodrugs of excitatory amino acids
US20040248963A1 (en) * 2001-11-23 2004-12-09 Bueno Melendo Ana Belen Prodrugs of excitatory amino acids
US7456221B2 (en) * 2001-12-21 2008-11-25 Eli Lilly And Company Prodrugs of excitatory amino acids
US20040116489A1 (en) * 2002-02-12 2004-06-17 Massey Steven Marc Synthetic excitatory amino acids
US20030182669A1 (en) * 2002-03-19 2003-09-25 Rockman Howard A. Phosphoinositide 3-kinase mediated inhibition of GPCRs
US20050192273A1 (en) * 2002-04-03 2005-09-01 Johnson Bryan G. Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist
US7290215B2 (en) * 2002-06-03 2007-10-30 Microsoft Corporation Dynamic wizard interface system and method
SI1637517T1 (sl) * 2003-06-26 2011-01-31 Taisho Pharmaceutical Co Ltd Derivat estra 2-aminobiciklo 3.1.0 heksan-2,6-dikarboksilne kisline
US20060252743A1 (en) * 2005-01-07 2006-11-09 Astrazeneca Ab Method of treating sleep disorders
US20090093461A1 (en) * 2003-07-02 2009-04-09 Astrazeneca Ab Methods of Treating Anxiety and Mood Disorders
US20060217366A1 (en) * 2003-07-02 2006-09-28 Astrazeneca Ab Method of treating schizophrenia and other disorders
US20060217367A1 (en) * 2004-07-01 2006-09-28 Astrazeneca Ab Method of treating anxiety disorders
CA2531284A1 (en) * 2003-07-02 2005-01-13 Astrazeneca Ab Metabolite of quetiapine
US20070117789A1 (en) * 2005-11-18 2007-05-24 Astrazeneca Ab Method of treatment
US20060229292A1 (en) * 2005-01-07 2006-10-12 Astrazeneca Ab Method of treating childhood disorders
US20090093460A1 (en) * 2003-07-02 2009-04-09 Astrazeneca Ab Compositions
US20060217365A1 (en) * 2003-07-02 2006-09-28 Astrazeneca Ab Method of treating mood disorders
US7795266B2 (en) * 2003-09-25 2010-09-14 Helton David R Tetrahydroindolone derivatives for treament of neurological conditions
CN100475800C (zh) * 2003-11-07 2009-04-08 大正制药株式会社 二环[3.1.0]己烷衍生物的制备方法及其中间体
US20050107439A1 (en) * 2003-11-10 2005-05-19 Helton David R. Composition and method for treating emesis
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
EP1942879A1 (en) 2005-10-31 2008-07-16 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
JP2010502722A (ja) 2006-09-08 2010-01-28 ブレインセルス，インコーポレイティド ４−アシルアミノピリジン誘導体を含む組み合わせ
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2219648A4 (en) * 2007-11-09 2010-11-03 Cenomed Biosciences Llc TREATMENT OF POSTRAUMATIC STRESS WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS
US20090264443A1 (en) * 2008-04-18 2009-10-22 David Helton Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
TWI488854B (zh) 2008-06-20 2015-06-21 Astrazeneca Ab 二苯并噻氮呯衍生物及其用途
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2019025931A1 (en) 2017-07-31 2019-02-07 Novartis Ag USE OF A MUSSEL FOR REDUCING THE USE OF COCAINE OR FOR PREVENTING A RECHUTE IN THE USE OF COCAINE

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3532744A (en) * 1967-07-28 1970-10-06 American Home Prod 1- and 2-amino substituted indane and tetralene carboxylic acids
US3704312A (en) * 1970-10-30 1972-11-28 American Home Prod Bialicyclic amino acids
US3746495A (en) * 1971-06-01 1973-07-17 American Home Prod Anti-ulcer therapy
GB9325368D0 (en) * 1993-12-10 1994-02-16 Univ Bristol Organic compounds

Also Published As

Publication number Publication date
UA43332C2 (uk) 2001-12-17
KR960007545A (ko) 1996-03-22
BR9503638A (pt) 1996-05-28
KR100375463B1 (ko) 2003-04-23
US5661184A (en) 1997-08-26
US5750566A (en) 1998-05-12

Similar Documents

Publication Publication Date Title
CO4410321A1 (es) Compuestos ciclicos condensados con funciones aminoacidas sustituidas y derivados ester de los mismos
ES2121988T3 (es) Derivado de morfinano y uso medicinal.
FR2518088B1 (fr) Nouveaux derives d'aminoacides, et leur application therapeutique
DE69010139T2 (de) Haarkräftigungsmittel.
ES8704924A1 (es) Un procedimiento para la preparacion de derivados de benzotiazol y benzotiofeno
CO4410181A1 (es) Derivado de 2-(2-amino-1,6-dihidro-6-oxo-purin-9-il) metoxi-1,3-propandiol
ES2155566T3 (es) Uso de derivados de rifamicina para el tratamiento de enfermedades infecciosas por clamidia.
GB9408185D0 (en) New benzamide derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
DE3670081D1 (de) Imidazolderivate, verfahren zu deren herstellung, deren anwendung und pharmazeutische zusammenstellungen.
BR9506552A (pt) Método de inibição de integrase retroviral
KR890011596A (ko) 불면증 치료용 의약품의 제조에 있어서 1,4-이치환-피페리디닐 화합물의 용도
DK624989D0 (da) Hidtil ukendte forbindelser
PT900082E (pt) Utilizacao de piridilpiperazina e pirimidilpiperazina para o fabrico de um medicamento para o tratamento de perturbacoes de toxicomania
ES2112994T3 (es) Analogos de clomifeno no metabolizables utilizados en el tratamiento de tumores resistentes al tamoxifeno.
AR034088A1 (es) Composicion que comprende derivados anticonvulsivantes utiles en el tratamiento de esquizofrenia y el uso de dicho derivado para la manufactura de un medicamento
FI904449A0 (fi) N-azasicyklo/3.3.0/oktanamider av aromatiska syror.
FR2637499A1 (fr) Medicaments a base de nouveaux derives de la methoxycarbonyl-2 n, n'-di-(trimethoxybenzoyle) piperazine
ATE65986T1 (de) Propanolabkoemmlinge.
SE9603284D0 (sv) New compounds
AR241434A1 (es) Procedimiento para la preparacion de 3-(piperidinil)-1h-indazoles.
TH6029A (th) อนุพันธ์ของควิโนลิเนียม และไอโซควิโนลิเนียมที่ควบแน่น
DE69704759T2 (de) Ellipticinederivate, ihre Herstellung und diese enthaltende pharmazeutische Zubereitungen
TH6029EX (th) อนุพันธ์ของควิโนลิเนียม และไอโซควิโนลิเนียมที่ควบแน่น